Dengue Fever is a disease caused by infection with the dengue virus in mosquito. Data from the Indonesian Ministry of Health states that DBD cases in Indonesia will reach 131,265 cases in 2022.
In September 2022, the Food and Drug Supervisory Agency (BPOM) officially granted distribution permits for the Dengue vaccine (Qdenga). This is the second Dengue vaccine that has a distribution permit from BPOM after Dengvaxia. Here are the facts about the dengue vaccine that you should know.
Given to ages 6–45 years
The Qdenga vaccine can be given to people aged 6 to 45 years. This vaccine is registered under the name of PT Takeda Indonesia and is produced by IDT Biologika GmbH Germany.
The vaccine is given in two doses with an interval of three months between doses.
For children under 6 years of age, current clinical study data indicate vaccine effectiveness at this age is lower than in the 6–45 year age group. Currently there is no data on the effectiveness of the Qdenga vaccine for people over 45 years of age.
Can prevent dengue fever up to 80.2 percent
The effectiveness of the Qdenga vaccine is demonstrated by phase 3 clinical study data and is supported by immunogenicity data from phase 3 and phase 2 clinical studies. Overall, the effectiveness of this vaccine can prevent DHF by 80.2 percent, while its effectiveness for preventing hospitalization due to dengue virus is 95.4 percent .
Both subjects who had antibodies or not against dengue virus had good efficacy. For safety analysis at the age of 6–45 years, the Qdenga vaccine is overall safe and well tolerated.
Dengue vaccine side effects
From BPOM’s analysis, the side effects of the Qdenga dengue vaccine are generally mild to moderate. Local side effects reported were pain at the injection site, erythema (red spots), and transient swelling. These side effects will usually disappear within 1-3 days after administration of the vaccine.
Reported systemic side effects include headache, muscle aches, malaise, tiredness, irritability, drowsiness, loss of appetite and fever.
There were no bleeding events after administration of the vaccine. Hypersensitivity reactions have a presentation below 0.1 percent of all subjects.
Dengue vaccine can provide protection for many years
The duration of vaccine protection is still being studied. Reported by the United States Centers for Disease Control and Prevention (CDC). Until now, it is known that vaccines can provide protection against DBD for at least 6 years.
Over time with the administration of the dengue vaccine, researchers will continue to see how long the vaccine can protect the recipient.
Dengue fever vaccine price range
Dr. Choo Beng Goh, Head of Medical Affairs APAC Takeda, said that the price of the DHF vaccine could vary depending on the health care provider who administered the vaccine.
Be First to Comment